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With the revolution in direct-acting antivirals for hepatitis C
upon us, it’s important not to lose track of another of our
specialty’s great challenges, the fatty liver disease epidemic.
The payoff of direct-acting HCV antivirals required 22 years from
the discovery of the virus in 1989 [4], yet 31 years after the
description of NASH [1,10] we are still struggling to understand
its pathogenesis, management, and impact. Two articles in this
month’s issue offer incremental progress toward that goal.
A concise yet informative study by Tandra and colleagues
derived from the NIH NASH Clinical Research Network deﬁnes a
subset of 10% of 1022 patients with the disease whose biopsies
demonstrate microvesicular steatosis rather than macrovesicular
steatosis. This ﬁnding was strongly correlated with several histo-
logic features of more aggressive disease, including ballooning
cell injury, Mallory-Denk bodies, NASH activity scores, and
advanced ﬁbrosis, among others. Megamitochondria, a hallmark
of mitochondrial disruption, were also prominent. Microvesicular
steatosis, deﬁned as ‘‘non-zonal, contiguous patches of foamy
hepatocytes with centrally placed nuclei’’, and illustrated by a ﬁg-
ure in the Tandra paper, is typically associated with impairment
in the mitochondrial b-oxidation of fatty acids [8,21], either due
to congenital metabolic disorders or drugs, including Reye’s syn-
drome. As fatty acids accumulate in the absence of oxidation they
may be esteriﬁed into triglycerides and thereby accumulate in
droplets. The development of small rather than large vacuoles
may reﬂect the acuity of the insult, such that there is insufﬁcient
time for small vacuoles to coalesce into larger ones. Alternatively,
impaired clearance of hepatic fat may also lead to lipid droplet
accumulation. Either reduced VLDL secretion or defects in micro-
somal transfer protein (MTP), which normally transfers lipids to
apolipoprotein B for packaging into VLDL, can contribute to
reduced clearance.
These precipitants of microvesicular steatosis may provide
some clues into the signiﬁcance of this ﬁnding in patients with
fatty liver. An appealing hypothesis is that patients with microve-
sicular steatosis have a speciﬁc genetic polymorphism or defect
in fatty acid metabolism that is unearthed in the setting of con-
current metabolic syndrome and fatty liver, an example of the
‘two-hit’ concept. Perhaps the fatty liver-associated SNP in the
PNPLA3 gene [18] is contributing? Alternatively, applying an
unbiased genome wide association study of the type that yielded
the PNPLA3 might expose new genetic variants that inﬂuence theJournal of Hepatology 20
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which in turn could reveal new pathogenetic clues to NASH.
Because the patients with or without microvesicular steatosis
were matched in terms of NASH risk factors (e.g., BMI, HOMA
and AST/ALT), it would seem unlikely that a genetic risk factor
leading to microvesicular steatosis occurs ﬁrst and then leads
to features of fatty liver disease, but this remains a possibility.
Since this is a cross-sectional rather than a longitudinal study,
one cannot determine whether microvesicular steatosis and asso-
ciated abnormalities are present throughout the course of disease
in these speciﬁc patients, or instead that the ﬁndings are evanes-
cent and occur transiently in many more patients. Moreover,
these more aggressive histologic features would be predicted to
accelerate ﬁbrosis, but long-term follow-up is required to vali-
date this prediction.
Finally, the identiﬁcation of a subset of patients with unique
histologic features among those with fatty liver disease required
the large and highly integrated approach of the NASH Clinical
Research Network. The ﬁndings underscore the importance of
large numbers of patients who are meticulously phenotyped by
experts in order to generate robust, novel clinical, and genetic
data, especially in those with the metabolic syndrome [11].
While the access to liver biopsies in a large number of patients
proved critical to identifying a subset with microvesicular steato-
sis among those with fatty liver disease, the reality is that biopsy
is not a routine management tool in clinical practice when fatty
liver disease is suspected, and its role is unsettled. Concurrently,
non-invasive measures of liver injury, inﬂammation, fat, and
ﬁbrosis are steadily improving. For example, measurement of
liver stiffness using transient elastography is increasingly
accepted as a surrogate for inﬂammation, edema, and/or ﬁbrosis
in viral liver disease [3,19], and helps discriminate ﬁbrosis stage
in fatty liver disease as well [5], although not as clearly as in viral
hepatitis [9]. Even more exciting has been the evidence that liver
stiffness values predict the likelihood of portal hypertensive com-
plications in patients with chronic liver disease, with an accuracy
comparable to hepatic venous pressure gradient [17]. These ﬁnd-
ings parallel recent studies demonstrating the prognostic value of
serum tests under similar conditions [13]. Prognostic data of this
type add momentum toward the use of non-invasive markers as
endpoints in clinical trials, especially since liver stiffness may
improve in response to effective therapies [12,22].
While transient elastography has been widely accepted in
Europe and Asia, its use in the United States has been limited,
owing in part to the high cost of the devices and lack of approval
by the Food and Drug Administration, preventing providers from
recovering the costs of its purchase through reimbursement from11 vol. 55 j 503–504
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patients or insurers. Moreover, in the case of fatty liver disease,
severe adiposity limits its utility [2], although newer probes are
under development to circumvent this problem [6].
Acoustic radiation force impulse (ARFI) is a newer ultrasound-
based alternative to transient elastography that also measures
stiffness, but can be incorporated into a conventional ultrasound
device. A handful of papers have been reported using this tech-
nology in liver disease, which measures a region of interest of
5  4 mm [7,14–16,20]. The technique reportedly has accuracy
comparable to transient elastography in patients with chronic
HCV [7], but experience is far more limited.
In the article by Palmeri and colleagues in this issue of the
Journal of Hepatology, ARFI has been used in patients with NALFD,
correlating the ﬁndings with speciﬁc histologic features on liver
biopsies in 172 patients. The test was generally useful (90% sen-
sitivity and speciﬁcity) in distinguishing between low ﬁbrosis
stage (0–2) and high ﬁbrosis stage (3–4). There was no correla-
tion between inﬂammation or hepatocyte ballooning, however.
More encouraging was its utility even in obese patients, where
transient elastography still poses challenges, although only a
small number of obese patients were tested. While the data are
preliminary and not thoroughly convincing, they are another
example of the accelerating pace of technology development for
non-invasive assessment of ﬁbrosis and cirrhosis.
Along with other approaches including MRI techniques, serum
markers, and metabolic breath tests, transient elastography and
ARFI are expanding the prospects for using non-invasive markers
alone or combination to assess disease stage and prognosis. To
derive the most information from testing of these markers,
prospective studies should be designed comparing as many
techniques as possible head-to-head in the same patients, and
correlating the results with clinical features, short- and long-term
outcomes, and response to disease therapies. Minimizing the cost
of new technologies and improving the quality of the data will
enhance their appeal, and help usher in a new era of liver disease
diagnosis.Conﬂict of interest
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